medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-12-113-117medsovet-1173Research ArticleРЕВМАТОЛОГИЯRHEUMATOLOGYБолевой синдром в ревматологииPain syndrome in rheumatologyШостакН. А.ShostakN. А.noemail@neicon.ruПравдюкН. Г.PravdyukN. G.noemail@neicon.ruКлименкоА. А.KlimenkoA. A.noemail@neicon.ruКондрашовА. А.KondrashovA. A.noemail@neicon.ruРНИМУ им. Н.И. Пирогова, МоскваРоссияPirogov Russian National Research Medical University, MoscowRussian Federation201330122013012113117Copyright © Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А., 20132013Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А.Shostak N.А., Pravdyuk N.G., Klimenko A.A., Kondrashov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1173

В статье представлены разновидности болевых синдромов при ревматических заболеваниях - остеоартрозе и подагре. Описаны наиболее распространенные и социально значимые клинические варианты остеоартроза - гонартроз и коксартроз, освещены подходы к терапии болевого синдрома при указанной патологии. Подробно освещен алгоритм ведения больного с подагрой. Рассмотрены основные медикаментозные подходы к лечению болевого синдрома при ревматических заболеваниях.

The article tells about types of pain at such rheumatic diseases as osteoarthritis and gout. The most common and socially significant clinical types of osteoarthritis - gonarthrosis and coxarthrosis, and approaches to treatment of pain in these pathologies, are described. The process of treatment of gout patient is described in detail. The main approaches to medicine-based treatment of pain syndrome at rheumatic disease are highlighted.

болевой синдромостеоартрозкоксартрозгонартрозподаграподагрический артритНПВПдиклофенакpain syndromeosteoarthritiscoxarthrosisgonarthrosisgoutgouty arthritisNSAIDsdiclofenacReferencesАлексеева Л.И., Зайцева Е.М. Субхондральная кость при остеоартрозе: новые возможности терапии. РМЖ, 2004;12(20):1133-1136.Алексеева Л.И., Зайцева Е.М. Субхондральная кость при остеоартрозе: новые возможности терапии. РМЖ, 2004;12(20):1133-1136.Павлова В.Н., Павлов ГГ., Шостак Н.А., Слуцкий Л.И. Сустав: морфология, клиника, диагностика, лечение. М.: ООО «Издательство «Медицинское информационное агентство», 2011.Павлова В.Н., Павлов ГГ., Шостак Н.А., Слуцкий Л.И. Сустав: морфология, клиника, диагностика, лечение. М.: ООО «Издательство «Медицинское информационное агентство», 2011.Ревматология: учеб. пособие / под ред. Н.А. Шостак М.: ГЭОТАР-Медиа, 2012.Ревматология: учеб. пособие / под ред. Н.А. Шостак М.: ГЭОТАР-Медиа, 2012.Altman R, Asch E, Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum.,1986;29(8):1039-1049.Altman R, Asch E, Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum.,1986;29(8):1039-1049.Altman R, Alarcon G, Appelrouth D. et al. The American College of Reumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum, 1991;34:505-514.Altman R, Alarcon G, Appelrouth D. et al. The American College of Reumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum, 1991;34:505-514.Dinesh Khanna, John D. Fitzgerald, Puja P. Khanna et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research, 64(10) October 2012:1431-1446.Dinesh Khanna, John D. Fitzgerald, Puja P. Khanna et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research, 64(10) October 2012:1431-1446.Насонова В.А. Вольтарен (диклофенак натрия) в ревматологии в начале XXI века. РМЖ, 2004;12(6):1380-1385.Насонова В.А. Вольтарен (диклофенак натрия) в ревматологии в начале XXI века. РМЖ, 2004;12(6):1380-1385.Solomon DH, Glynn RJ, Rothman KJ. et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum, (Arthritis Care Res), 2008;59:1097-104.Solomon DH, Glynn RJ, Rothman KJ. et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum, (Arthritis Care Res), 2008;59:1097-104.Schwartz JI, Van Hecken A, De Lepeleire I. et al. Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofen and naproxen on COX-2 VS COX-1 in healthy female volunteers. Poster EULAR 1999. Ann. Rheum. Dis, 1998;57:206.Schwartz JI, Van Hecken A, De Lepeleire I. et al. Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofen and naproxen on COX-2 VS COX-1 in healthy female volunteers. Poster EULAR 1999. Ann. Rheum. Dis, 1998;57:206.McKenna F, Borenstein D, Wendt H. et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand. J. Rheumatol., 2001;30 (1):11-18.McKenna F, Borenstein D, Wendt H. et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand. J. Rheumatol., 2001;30 (1):11-18.Cannon GW, Caldwell JR, Holt P. et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum, 2000;43 (5):978-987.Cannon GW, Caldwell JR, Holt P. et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum, 2000;43 (5):978-987.Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol., 2003;15:173-178.Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol., 2003;15:173-178.Biaco F, Guitian R, Moreno I. et al. NSAIDs effect on COX-1 and COX-2 activity in human articular chondrocytes. Arthr. Rheum., 1997;40:88.Biaco F, Guitian R, Moreno I. et al. NSAIDs effect on COX-1 and COX-2 activity in human articular chondrocytes. Arthr. Rheum., 1997;40:88.

The authors declare that there are no conflicts of interest present.